JP2016003187A5 - - Google Patents

Download PDF

Info

Publication number
JP2016003187A5
JP2016003187A5 JP2014122464A JP2014122464A JP2016003187A5 JP 2016003187 A5 JP2016003187 A5 JP 2016003187A5 JP 2014122464 A JP2014122464 A JP 2014122464A JP 2014122464 A JP2014122464 A JP 2014122464A JP 2016003187 A5 JP2016003187 A5 JP 2016003187A5
Authority
JP
Japan
Prior art keywords
schizophrenia
bifidobacterium
therapeutic agent
active ingredient
genus bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014122464A
Other languages
English (en)
Japanese (ja)
Other versions
JP6234331B2 (ja
JP2016003187A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014122464A priority Critical patent/JP6234331B2/ja
Priority claimed from JP2014122464A external-priority patent/JP6234331B2/ja
Publication of JP2016003187A publication Critical patent/JP2016003187A/ja
Publication of JP2016003187A5 publication Critical patent/JP2016003187A5/ja
Application granted granted Critical
Publication of JP6234331B2 publication Critical patent/JP6234331B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014122464A 2014-06-13 2014-06-13 統合失調症治療剤 Expired - Fee Related JP6234331B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014122464A JP6234331B2 (ja) 2014-06-13 2014-06-13 統合失調症治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014122464A JP6234331B2 (ja) 2014-06-13 2014-06-13 統合失調症治療剤

Publications (3)

Publication Number Publication Date
JP2016003187A JP2016003187A (ja) 2016-01-12
JP2016003187A5 true JP2016003187A5 (pl) 2016-12-28
JP6234331B2 JP6234331B2 (ja) 2017-11-22

Family

ID=55222737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014122464A Expired - Fee Related JP6234331B2 (ja) 2014-06-13 2014-06-13 統合失調症治療剤

Country Status (1)

Country Link
JP (1) JP6234331B2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017130859A1 (ja) * 2016-01-28 2018-11-15 森永乳業株式会社 神経細胞死抑制剤
JP2023511678A (ja) * 2020-01-24 2023-03-22 森永乳業株式会社 神経突起伸長改善用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
MX2011013258A (es) * 2009-06-11 2012-02-28 Angiochem Inc Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central.
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
RU2557310C2 (ru) * 2009-11-11 2015-07-20 Алиментари Хелс Лимитед ШТАММ Bifidobacterium longum, ПРИГОДНЫЙ ДЛЯ ПРИМЕНЕНИЯ В ИММУНОМОДУЛЯЦИИ, ИНДУКЦИИ ПРОДУКЦИИ ЦИТОКИНОВ, ЛЕЧЕНИИ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, КОНТРОЛЕ ОТНОШЕНИЯ IL - 10:IL - 12, И ЕГО ИСПОЛЬЗОВАНИЕ
US9452189B2 (en) * 2010-10-07 2016-09-27 California Institute Of Technology Probiotic therapies for autism
JP5774517B2 (ja) * 2012-02-22 2015-09-09 森永乳業株式会社 ビフィドバクテリウム属細菌含有発酵食品の製造方法

Similar Documents

Publication Publication Date Title
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MY186217A (en) Mixture of hmos
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
MX2019014045A (es) Composiciones y metodos.
WO2015114666A3 (en) Treatments for resistant acne
HK1254897A1 (zh) 用於治療由痤瘡丙酸桿菌引起的感染尤其是痤瘡的乳酸菌的組合物
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
IN2012DN01638A (pl)
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EA201992176A1 (ru) Пробиотические молекулы для снижения вирулентности патогена
BR112017010475A2 (pt) cepas de lactobacillus ou bifidobacterium para manter homeostase
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
GB2511993A (en) Prebiotic formulations and methods of use
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
PH12016501988A1 (en) Antibacterial compounds
TN2016000435A1 (en) Novel macrocyclic compounds.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016100615A3 (en) Methods and composition for neutralization of influenza
AU2018225957A1 (en) Composition for alleviating mental health disorder
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions